Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro-DexPDEX -0.03%66 Cash-to-Debt is 0.57 as of Mar. 2026, which is 24% below its 10-year median of 0.75. GuruFocus rates PDEX with a GF Score™ of 66/100 and a GF Value™ of $40.81 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Pro-Dex ranks worse than 69.11% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pro-Dex's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.57.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Pro-Dexcouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Pro-Dex's Cash-to-Debt or its related term are showing as below:
PDEX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1 Med: 0.75 Max: 180.68
Current: 0.57
During the past 13 years, Pro-Dex's highest Cash to Debt Ratio was 180.68. The lowest was 0.10. And the median was 0.75.
PDEX's Cash-to-Debt is ranked worse than 69.11% of 845
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs PDEX: 0.57
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Pro-Dex Cash-to-Debt Related Terms
Pro-Dex Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Pro-Dex's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Pro-Dex's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro-Dex Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Pro-Dex's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex (PDEX) has a Cash-to-Debt of 0.57 as of Mar. 2026. This is 24% below median its historical median of 0.75. Over the past decade, Pro-Dex's Cash-to-Debt has ranged from 0.10 to 180.68. According to the industry distribution chart, Pro-Dex ranks #584 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 69.1%.
Is Pro-Dex's Cash-to-Debt too high?
Pro-Dex's current Cash-to-Debt of 0.57 is 24% below median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 180.68. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Pro-Dex's value of 0.57 is 66.1% below this industry median. Based on the distribution chart, Pro-Dex ranks #584 out of 845 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pro-Dex has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's Cash-to-Debt compare to KRMD and EMBC?
According to the Medical Devices & Instruments industry distribution chart, Pro-Dex ranks #584 out of 845 companies for Cash-to-Debt. This places Pro-Dex in the lower half of its industry. The industry median Cash-to-Debt is 1.68. Pro-Dex's value of 0.57 is 66.1% below this benchmark. Historically, Pro-Dex's own Cash-to-Debt has ranged from 0.10 to 180.68 over the past decade. While the company's 10-year median is 0.75 vs. the industry median of 1.68, Pro-Dex has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro-Dex's current Cash-to-Debt of 0.57 is 66.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current Cash-to-Debt is 0.57, which is 24% below median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (PDEX) is currently considered Significantly Overvalued. The stock's GF Value™ is $40.81, compared to a current price of $66.76 — trading 63.6% above its estimated fair value. The current Cash-to-Debt is 0.57, which is 24% below median its 10-year median of 0.75 and 66.1% below the Medical Devices & Instruments industry median of 1.68. Pro-Dex's overall GF Score™ is 66/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Pro-Dex (PDEX), the current Cash-to-Debt is 0.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro-Dex (PDEX) Overvalued in 2026?
Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued.
The current stock price of $66.76 is trading 63.6% above its estimated GF Value™ of $40.81.
GuruFocus considers Pro-Dex to be Significantly Overvalued.
Key valuation signals for PDEX:
Cash-to-Debt: 0.57 (24% below median its 10-year median of 0.75)
GF Value™: $40.81 vs. price of $66.76 (63.6% above fair value)
Industry Position: 66.1% below the Medical Devices & Instruments median (#584 of 845)
No single metric tells the full story. See the PDEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
66GF Score
Get the complete analysis for PDEX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDEX has been successfully added to your 
